Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 59 results for dyspepsia

  1. Irritable bowel syndrome in adults: diagnosis and management (CG61)

    This guideline covers diagnosing and managing irritable bowel syndrome (IBS) in people aged 18 and over. It details how to accurately diagnose IBS, and aims to improve the quality of life for adults with IBS by promoting effective management using dietary and lifestyle advice, pharmacological therapy and referral for psychological interventions.

    Clinical guideline
    Last updated
    4 April 2017
    View recommendations

    Sections for CG61

  2. Type 2 diabetes: insulin degludec/liraglutide (Xultophy) (ESNM60)

    Summary of the evidence on insulin degludec/liraglutide (Xultophy) for treating type 2 diabetes to inform local NHS planning and decision-making

    Evidence summary
    Published
    3 July 2015

  3. Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B (TA96)

    Evidence-based recommendations on adefovir dipivoxil (Hepsera) and peginterferon alfa-2a (Pegasys) for treating chronic hepatitis B in adults.

    Technology appraisal guidance
    Published
    22 February 2006
    View recommendations

    Sections for TA96

  4. Gastroparesis in adults: oral erythromycin (ESUOM13)

    Summary of the evidence on oral erythromycin for gastroparesis (delayed stomach emptying) in adults to inform local NHS planning and decision-making

    Evidence summary
    Published
    18 June 2013

  5. Suspected cancer (QS124)

    This quality standard covers the investigation and recognition of suspected cancer, and referral to specialist cancer services for adults, young people and children. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    5 December 2017
    View quality statements

    Sections for QS124

  6. Laparoscopic insertion of an inactive implant for gastro-oesophageal reflux disease (HTG749)

    Evidence-based recommendations on laparoscopic insertion of an inactive implant for gastro-oesophageal reflux disease. This involves placing an implant on the outside of the upper part of the stomach wall using keyhole surgery.

    HealthTech guidance
    Published
    3 June 2025
    View recommendations

    Sections for HTG749

  7. Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA327)

    Evidence-based recommendations on dabigatran etexilate (Pradaxa) for treating and preventing deep vein thrombosis and pulmonary embolism in adults.

    Technology appraisal guidance
    Published
    17 December 2014
    View recommendations

    Sections for TA327

  8. Infliximab for acute exacerbations of ulcerative colitis (TA163)

    Evidence-based recommendations on infliximab (Remicade) for treating acute exacerbations of severely active ulcerative colitis in adults.

    Technology appraisal guidance
    Published
    17 December 2008
    View recommendations

    Sections for TA163

  9. In people who experience symptoms of gastro-oesophageal reflux disease (GORD) or symptoms suggestive of GORD, what patient characteristics, risk factors and predictors indicate when endoscopy is needed to exclude Barrett's oesophagus?

    details Comes from guidance Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management Number CG184 Date

    Research recommendation
    Published
    15 November 2019

  10. What is the effectiveness of laparoscopic fundoplication compared with medical management in people with GORD that does not respond to optimal proton pump inhibitor (PPI) treatment?

    details Comes from guidance Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management Number CG184 Date

    Research recommendation
    Published
    15 November 2019

  11. Laparoscopic fundoplication compared with medical management:- What is the effectiveness of laparoscopic fundoplication compared with medical management in people with GORD that does not respond to optimal proton pump inhibitor (PPI) treatment?

    details Comes from guidance Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management Number CG184 Date

    Research recommendation
    Published
    9 June 2015

  12. Acute coronary syndromes (NG185)

    This guideline covers the early and longer-term (rehabilitation) management of acute coronary syndromes. These include ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina. The guideline aims to improve survival and quality of life for people who have a heart attack or unstable angina.

    NICE guideline
    Published
    18 November 2020
    View recommendations

    Sections for NG185

  13. Patient characteristics, risk factors and predictors that indicate endoscopy for excluding Barrett's oesophagus:- In people who experience symptoms of gastro-oesophageal reflux disease (GORD) or symptoms suggestive of GORD, what patient characteristics, risk factors and predictors indicate when endoscopy is needed to exclude Barrett's oesophagus?

    details Comes from guidance Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management Number CG184 Date

    Research recommendation
    Published
    9 June 2015

  14. What is the clinical effectiveness of double-dose PPIs in people with severe erosive reflux disease (Los Angeles classification grade C/D or Savary–Miller grade 3/4): to reduce severe oesophagitis to control symptoms as maintenance therapy?

    details Comes from guidance Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management Number CG184 Date

    Research recommendation
    Published
    15 November 2019

  15. What specialist management is effective for people whose symptoms do not respond to PPIs despite optimum primary care, or for people whose symptoms return after surgery?

    details Comes from guidance Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management Number CG184 Date

    Research recommendation
    Published
    15 November 2019